A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.